epigallocatechin gallate has been researched along with Malaria in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crawford, AD; Esguerra, CV; Franzblau, SG; Lauinger, IL; Maes, L; Perozzo, R; Pham, DH; Stairiker, C; Tarun, A; Tasdemir, D; Tonge, PJ; Vivas, L; Xu, H; Zhang, X; Zloh, M | 1 |
| Andricopulo, AD; Bwalya, AG; Carballeira, NM; Cordero-Maldonado, ML; Crawford, AD; Guido, RV; Itoe, MA; Kaiser, M; Mota, MM; Tasdemir, D | 1 |
| Akoto, M; Avery, VM; Duffy, S; Hagen, TJ; Helgren, TR; Igbinoba, O; Lee, P; Sciotti, RJ | 1 |
3 other study(ies) available for epigallocatechin gallate and Malaria
| Article | Year |
|---|---|
Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.
Topics: Animals; Antimalarials; Disease Models, Animal; Enzyme Inhibitors; Fatty Acid Synthase, Type II; Hepatocytes; Humans; Lichens; Liver; Malaria; Molecular Structure; Mycobacterium tuberculosis; Plasmodium berghei; Plasmodium falciparum; Protozoan Proteins; Staphylococcus aureus; Zebrafish | 2013 |
2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes.
Topics: Animals; Antimalarials; Cell Line, Tumor; Dose-Response Relationship, Drug; Fatty Acid Synthase, Type II; Fatty Acids, Unsaturated; Humans; Malaria; Models, Molecular; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship; Zebrafish | 2014 |
The synthesis, antimalarial activity and CoMFA analysis of novel aminoalkylated quercetin analogs.
Topics: Antimalarials; Humans; Malaria; Models, Molecular; Molecular Structure; Plasmodium falciparum; Quantitative Structure-Activity Relationship; Quercetin; Stereoisomerism | 2015 |